SIOX Stock Price, Sio Gene Therapies, Inc. Quote, Chart

Market Summary

USD0.48

Market Closed

SIOX Stock Price

View Fullscreen

SIOX RSI Chart

SIOX Valuation

Market Cap

35.5M

Price/Earnings (Trailing)

-1.23

Price/Free Cashflow

-0.97

SIOX Price/Earnings (Trailing)

SIOX Profitability

Free Cashflow Yield

-102.82%

SIOX Fundamentals

SIOX Earnings

Breaking Down SIOX Revenue

Last 7 days

18.0%

Trailing 12 Months

3.1%

How does SIOX drawdown profile look like?

SIOX Financial Health

SIOX Investor Care

Tracking the Latest Insider Buys and Sells of Sio Gene Therapies, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 08, 2021	nassif david w.	sold (taxes)	-8,937	1.42	-6,294	chief financial officer
Dec 08, 2021	nassif david w.	acquired	-	-	17,534	chief financial officer
Dec 08, 2021	cheruvu pavan	sold (taxes)	-21,135	1.42	-14,884	chief executive officer
Dec 08, 2021	cheruvu pavan	acquired	-	-	37,567	chief executive officer
Mar 23, 2021	cheruvu pavan	bought	248,180	2.4818	100,000	chief executive officer
Mar 22, 2021	nassif david w.	acquired	-	-	15,060	chief financial officer
Mar 17, 2021	cheruvu pavan	acquired	-	-	22,590	chief executive officer
Mar 17, 2021	corcoran gavin	acquired	-	-	16,001	chief r&d officer
Nov 24, 2020	pande atul	bought	23,399	2.3399	10,000	-

Which funds bought or sold SIOX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Nov 03, 2022	ACT CAPITAL MANAGEMENT, LLC	unchanged	-	-12,000	41,000	0.06%
Nov 12, 2021	Knott David M	-	-	-44,000	174,000	0.06%
Aug 13, 2021	QS Investors, LLC	new	-	222,000	222,000	-%

Are Funds Buying or Selling SIOX?

Are funds buying SIOX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SIOX

No. of Funds

Unveiling Sio Gene Therapies, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Feb 10, 2023	rubric capital management lp	9.46%	7e+06	SC 13G
Feb 14, 2022	consonance capital management lp	-	0	SC 13G/A
Feb 11, 2022	suvretta capital management, llc	8.1%	5,914,000	SC 13G/A

Sio Gene Therapies, Inc. News

Latest updates

Sio Gene Therapies, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Assets	-12.0%	47.00	54.00	62.00	75.00	93.00	111	122	135	99.00	80.00	71.00	94.00	42.00	76.00	101	123	96.00	102	108	161	196
Current Assets	-12.0%	47.00	54.00	59.00	72.00	90.00	109	119	132	97.00	70.00	61.00	85.00	33.00	67.00	92.00	115	91.00	96.00	102	158	193
Cash Equivalents	-7.5%	46.00	50.00	55.00	64.00	82.00	102	111	119	81.00	63.00	55.00	81.00	28.00	60.00	84.00	107	85.00	91.00	93.00	154	188
Net PPE	-	-	-	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00	3.00
Liabilities	-55.5%	2.00	5.00	11.00	15.00	17.00	11.00	9.00	12.00	10.00	10.00	12.00	32.00	37.00	59.00	72.00	66.00	73.00	82.00	82.00	90.00	90.00
Current Liabilities	-55.5%	2.00	5.00	9.00	13.00	15.00	10.00	8.00	11.00	9.00	10.00	12.00	32.00	31.00	47.00	54.00	43.00	45.00	49.00	44.00	47.00	42.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	12.00	18.00	23.00	28.00	33.00	38.00	43.00	48.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	15.00	9.00	23.00	22.00	21.00	21.00	20.00	15.00	10.00	5.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	12.00	18.00	23.00	28.00	33.00	38.00	43.00	48.00
Shareholder's Equity	-7.8%	45.00	49.00	52.00	60.00	76.00	99.00	113	123	89.00	70.00	59.00	62.00	5.00	17.00	29.00	56.00	23.00	20.00	26.00	71.00	107
Retained Earnings	-0.5%	-878	-874	-871	-862	-849	-824	-802	-791	-787	-777	-767	-758	-742	-728	-714	-686	-676	-642	-608	-556	-531
Additional Paid-In Capital	0.0%	923	923	923	923	926	923	916	914	876	847	826	820	747	745	743	741	699	662	634	628	637
Shares Outstanding	0%	74.00	74.00	74.00	74.00	73.00	73.00	73.00	69.00	53.00	47.00	43.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	117	-	-	-	132	-	-	-	61.00	-	-	-	79.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Cashflow From Operations	3.2%	-4,922	-5,083	-8,681	-17,822	-20,605	-9,267	-12,652	-10,241	-11,025	-11,820	-13,503	-17,910	-13,086	-18,746	-17,731	-11,583	-33,477	-27,734	-61,413	-34,200	-46,590
Share Based Compensation	5.6%	227	215	-159	856	400	1,400	1,321	960	800	1,100	1,590	3,559	100	1,100	2,135	4,513	4,200	900	5,859	-	9,900
Cashflow From Investing	-100.0%	-	177	-277	-359	-142	-14.00	4,163	12,633	-117	-111	-19.00	-5.00	-76.00	-96.00	-78.00	-128	-56.00	-18.00	-	-38.00	-603
Cashflow From Financing	-	-	-	-	-	962	-	479	36,759	28,990	19,620	-11,748	70,855	-19,281	-5,079	-5,014	33,771	27,746	25,544	10.00	324	71.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SIOX Income Statement

2022-12-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development expenses	$ 1,883	$ 21,287	$ 7,761	$ 40,793
General and administrative expenses	2,600	4,086	8,533	17,693
Total operating expenses	4,483	25,373	16,294	58,486
Other (income) expenses:
Other (income) expense, net	(464)	83	(785)	105
Loss before income tax benefit	(4,019)	(25,456)	(15,509)	(58,591)
Income tax benefit	0	0	(4)	(28)
Net loss	$ (4,019)	$ (25,456)	$ (15,505)	$ (58,563)
Net loss per share of common stock — basic (in dollars per share)	$ (0.05)	$ (0.35)	$ (0.21)	$ (0.80)
Net loss per share of common stock — diluted (in dollars per share)	$ (0.05)	$ (0.35)	$ (0.21)	$ (0.80)
Weighted-average shares of common stock outstanding — basic (in shares)	73,975,196	73,335,279	73,905,737	73,046,889
Weighted-average shares of common stock outstanding — diluted (in shares)	73,975,196	73,335,279	73,905,737	73,046,889

SIOX Balance Sheet

2022-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,127	$ 63,729
Restricted cash	0	1,184
Prepaid expenses and other current assets	789	5,214
Income tax receivable	356	1,609
Total current assets	47,272	71,736
Operating lease right-of-use assets	0	2,444
Property and equipment, net	0	900
Total assets	47,272	75,080
Current liabilities:
Accounts payable	201	3,984
Accrued expenses	1,951	8,232
Current portion of operating lease liabilities	0	786
Total current liabilities	2,152	13,002
Operating lease liabilities, net of current portion	0	1,730
Total liabilities	2,152	14,732
Commitments and contingencies
Stockholders’ equity:
Common stock, par value $0.00001 per share, 1,000,000,000 shares authorized, 73,975,196 and 73,739,378 issued and outstanding at December 31, 2022 and March 31, 2022, respectively	1	1
Additional paid-in capital	923,249	922,966
Accumulated deficit	(878,461)	(862,956)
Accumulated other comprehensive income	331	337
Total stockholders’ equity	45,120	60,348
Total liabilities and stockholders’ equity	$ 47,272	$ 75,080

About Sio Gene Therapies, Inc.

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

CEO	Mr. David W. Nassif J.D.
WEBSITE	siogtx.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Sio Gene Therapies, Inc. Frequently Asked Questions

What is the ticker symbol for Sio Gene Therapies, Inc.? What does SIOX stand for in stocks?

SIOX is the stock ticker symbol of Sio Gene Therapies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sio Gene Therapies, Inc. (SIOX)?

As of Wed Feb 07 2024, market cap of Sio Gene Therapies, Inc. is 35.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SIOX stock?

You can check SIOX's fair value in chart for subscribers.

What is the fair value of SIOX stock?

You can check SIOX's fair value in chart for subscribers. The fair value of Sio Gene Therapies, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sio Gene Therapies, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SIOX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sio Gene Therapies, Inc. a good stock to buy?

The fair value guage provides a quick view whether SIOX is over valued or under valued. Whether Sio Gene Therapies, Inc. is cheap or expensive depends on the assumptions which impact Sio Gene Therapies, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SIOX.